Trial Profile

DP13 - A Phase II Study in Patients With Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of DP13, Over an 8-week Treatment Period

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fadrozole (Primary)
Indications Hyperaldosteronism
Focus Therapeutic Use
Sponsors Damian Pharma

Most Recent Events

16 Jun 2022 Status changed from recruiting to completed.
17 Aug 2021 Planned End Date changed from 31 Dec 2020 to 30 Apr 2022.
17 Aug 2021 Planned primary completion date changed from 7 Sep 2020 to 31 Jan 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com